CVM - CEL-SCI Corporation

NYSE American - Nasdaq Real-time price. Currency in USD

CEL-SCI Corporation

8229 Boone Boulevard
Suite 802
Vienna, VA 22182
United States
703 506 9460

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Geert R. Kersten Esq.Chief Exec. & Financial Officer, Treasurer and Director681.99kN/A1959
Ms. Patricia B. PrichepSr. VP of Operations & Corp. Sec.286.03kN/A1951
Dr. Eyal Talor Ph.D.Chief Scientific Officer340.59kN/A1956
Dr. Daniel H. Zimmerman Ph.D.Sr. VP of Research & Cellular Immunology262.86kN/A1941
Mr. John CiprianoSr. VP of Regulatory Affairs239.1kN/A1942
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Corporate governance

CEL-SCI Corporation’s ISS governance QualityScore as of 1 May 2023 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.